Pricing Log in Create free account
Friday 6 November 2026 Export ABT’s income statement to Excel — free account

Abbott Laboratories

ABT Healthcare Medical Devices

Abbott Laboratories' revenue for fiscal 2025 (year ended December 2025) was $44.3 billion, up 5.67% from fiscal 2024.

Revenue
+14.5%
EPS
−43.6%
Free cash flow
+28.9%
Total debt
+140.8%

Quarter to September 2026, against a year earlier

110.08 3.52 −3.10%
Market cap
$196.6B
P/E
41.1×
Fwd P/E
35.1×
Dividend yield
2.29%
F-score
5/9
Altman Z
5.61
Beneish M
−2.50
Dividend safety
62/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Abbott Laboratories 10-Q filed Apr 29, 2026

Fiscal Q1 2026 · Period ended Mar 31, 2026 · Filed · accepted 4:05 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Oct 29, 2025: 15 added · 8 removed · 18 modified; 3 with only figures updated

  1. Modified · Financial Review — Results of Operations

    Abbott’s revenues are derived primarily from the sale of a broad lineportfolio of healthcare products under short-term receivable arrangements. Patent protection and licenses, technological and performance features, and inclusion of Abbott’s products under a contract most significantly impact which products are sold; price controls, competition, and rebates most significantly impact the net selling prices of products; and foreign currency translation impacts the measurement of net sales and costs. Abbott’s primary products are medical devices, diagnostic testing products, nutritional products, and branded generic pharmaceuticals.